Dillon Associates Inc buys $6,996,466 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Dillon Associates Inc scooped up 2,191 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 184,263 shares of Abbott Laboratories which is valued at $6,996,466.Abbott Laboratories makes up approximately 3.29% of Dillon Associates Inc’s portfolio.

Other Hedge Funds, Including , Middleton Co Incma reduced its stake in ABT by selling 164 shares or 0.25% in the most recent quarter. The Hedge Fund company now holds 64,656 shares of ABT which is valued at $2,454,988. Abbott Laboratories makes up approx 0.57% of Middleton Co Incma’s portfolio.Harding Loevner Lp reduced its stake in ABT by selling 67,726 shares or 2.52% in the most recent quarter. The Hedge Fund company now holds 2,622,049 shares of ABT which is valued at $99,559,201. Abbott Laboratories makes up approx 0.79% of Harding Loevner Lp’s portfolio.St. Johns Investment Management Company reduced its stake in ABT by selling 135 shares or 0.62% in the most recent quarter. The Hedge Fund company now holds 21,484 shares of ABT which is valued at $835,728. Abbott Laboratories makes up approx 0.74% of St. Johns Investment Management Company’s portfolio.Centurylink Investment Management Co reduced its stake in ABT by selling 1,415 shares or 3.62% in the most recent quarter. The Hedge Fund company now holds 37,657 shares of ABT which is valued at $1,659,921. Abbott Laboratories makes up approx 0.59% of Centurylink Investment Management Co’s portfolio.Dividend Asset Capital boosted its stake in ABT in the latest quarter, The investment management firm added 1,370 additional shares and now holds a total of 7,001 shares of Abbott Laboratories which is valued at $308,604. Abbott Laboratories makes up approx 0.01% of Dividend Asset Capital’s portfolio.

Abbott Laboratories opened for trading at $38.3 and hit $38.3 on the upside on Tuesday, eventually ending the session at $38.1, with a gain of 0.32% or 0.12 points. The heightened volatility saw the trading volume jump to 1,12,28,249 shares. Company has a market cap of $55,975 M.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.